Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
26 participants
INTERVENTIONAL
2025-11-12
2032-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions the study aims to answer in Phase/Part 1 of the trial are:
* Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.
* What is the most tolerable dose of \[Ac225\]RTX-2358
* Does the treatment show effectiveness on advanced sarcoma
Participants will:
* Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months
* Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests.
* For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests
* Remain in long term follow-up for a period of four additional years
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00124618
A Phase 1 Study of [225Ac]-FPI-1434 Injection
NCT03746431
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall
NCT02379845
Stereotactic Body Radiotherapy for Head and Neck Tumors
NCT01344356
Stereotactic Volumetric Radiotherapy in Prostate Cancer
NCT02423889
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of two phases, an ascending administered activity phase (Phase1) and an expansion phase (Phase 2). In the Phase 1 portion of the trial patients will be divided into three groups, each group receiving a higher dose than the last. A standard "3 + 3" dose escalation approach will be used, meaning three patients will start in each group, and more may be added if needed, to confirm safety.
Patients must be 18 or older, have soft tissue sarcoma that can be measured by imaging, and meet specific health requirements, including good organ function and a positive PET scan. Each treatment cycle in the phase 1 portion of the study involves a single injection on Day 1, followed by eight weeks of monitoring. Patients have a target of four cycles of treatment, with the possibility of two more (six maximum), if their side effects are mild and their disease hasn't worsened.
A Safety Review Committee (SRC) will review the data from each group in the Phase 1 portion to decide when it's safe to move to the next dose level. Once dose escalation of all cohorts is approved, patients can be added to two higher-dose groups to gather additional safety and preliminary data on effectiveness. Patients that receive at least one treatment in the Phase 1 portion of the study, will be followed for an initial period of 48 weeks for safety. After the first year, patients will have telephone check-ins every six months for up to four more years to track long-term safety, disease progression, and overall survival.
The Phase 2 portion of the study will evaluate the efficacy and safety of \[Ac225\]RTX-2358 on up to 50 patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with [Ac 225]RTX-2358
The study design is a 3+3 escalating group design.
[Ac 225]RTX-2358
\[Ac225\]RTX-2358 will be given as an intravenous injection once every 8 weeks for up to 6 doses. Each group (3 total) will receive a set administered activity level (dose) of \[Ac 225\]RTX 2358 given once every 8 weeks. The first group will received the lower dose, the second group will received the mid level dose, and the third group the highest dose. A Safety Review Committee will determine when/if it is appropriate to allow the next group to proceed.
[Cu64]LNTH-1363S
\[Cu64\]LNTH-1363S is a investigational radioactive diagnostic imaging agent to demonstrate that the tumor expresses Fibroblast Activation Protein. An imaging test is performed after a single injection with \[Cu64\]LNTH-1363S 13-35 days before the first administration of study drug \[AC225\]RTX-2358 to confirm that the sarcoma has FAP expression.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[Ac 225]RTX-2358
\[Ac225\]RTX-2358 will be given as an intravenous injection once every 8 weeks for up to 6 doses. Each group (3 total) will receive a set administered activity level (dose) of \[Ac 225\]RTX 2358 given once every 8 weeks. The first group will received the lower dose, the second group will received the mid level dose, and the third group the highest dose. A Safety Review Committee will determine when/if it is appropriate to allow the next group to proceed.
[Cu64]LNTH-1363S
\[Cu64\]LNTH-1363S is a investigational radioactive diagnostic imaging agent to demonstrate that the tumor expresses Fibroblast Activation Protein. An imaging test is performed after a single injection with \[Cu64\]LNTH-1363S 13-35 days before the first administration of study drug \[AC225\]RTX-2358 to confirm that the sarcoma has FAP expression.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of relapse and refractory soft tissue sarcoma.
1. Histological confirmation of sarcoma at any point since diagnosis
2. At least 1 prior treatment regimen
* Measurable disease as per RECIST (v1.1) for soft tissue sarcoma that is also positive on FAPi PET/CT or PET/MRI scan.
* ECOG performance status of 0 or 1.
* Adequate Organ reserve and renal function as evidenced by:
1. Neutrophil count ≥ 1200 µL without granulocyte colony stimulating factor
2. Platelet count ≥ 100,000 µL
3. Hemoglobin ≥ 8 g/dL
4. Total bilirubin level ≤ 1.5 × upper limit of normal (ULN).
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN.
6. Calculated creatinine clearance ≥ 60 mL/min. 6. Coagulation parameters (prothrombin time, international normalized ratio and activated partial thromboplastin time) ≤ 1.5 × ULN 7. All patients (males and females of childbearing potential) must agree to practice 2 forms of highly effective contraceptive precautions to prevent pregnancy from the time consent is signed and throughout the trial.
8\. The patient or the patient's legal representative must be willing and able to provide written informed consent.
Exclusion Criteria
* History of radioligand therapy.
* Treatment within 14 days prior to first administration with:
1. Palliative surgery or external beam radiation.
2. Approved anticancer therapy including chemotherapy or immunotherapy.
3. Any investigational therapy.
4. Any major surgery (e.g., requiring general anesthesia).
* Patients who are scheduled for external beam radiation therapy or radioligand therapy during the study period.
* Congestive heart failure \> Class II New York Heart Association Functional Classification, current pericarditis, myocardial infarction within 6 months, or symptomatic coronary artery disease.
* Patients with uncontrollable incontinence.
* Unstable or clinically significant concurrent medical condition that would, in the opinion of the Investigator, jeopardize the safety of a patient and/or their compliance with the protocol.
* Active infection requiring systemic antibacterial/antibiotic, antifungal, or antiviral therapy. Chronic antiviral therapy for stable viral disease can be included.
* History of active fibrotic condition.
* Any active malignancy other than sarcoma that requires treatment (.
* Currently pregnant or lactating.
* Known allergy to any of the study drugs or their excipients.- Inability or unwillingness to comply with any of the required imaging studies or study assessments.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ratio Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA
Los Angeles, California, United States
Mayo Clinic
Rochester, Minnesota, United States
Memorial Sloane Kettering Cancer Center
New York, New York, United States
Case Western
Cleveland, Ohio, United States
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RTX-2358-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.